SUMMARY
Conclusions. Quifenadine was extracted with chloroform at pH 9,0 from blood. Purification of extracts from co-extractive compounds was performed by combining TLC and extraction with hexane. It was established that when isolating quifenadine from blood according to the developed methods it is possible to allocate 32.5-37.6 % of substance (e = ± 6.65 %, RSDx = 2.25 %). The method of TLC purification and identification of quifenadine in biogenic extracts was tested under optimal conditions: system of organic solvents – chloroform-n-butanol-25 % solution of ammonium hydroxide (70:40:5), location reagents – UV light, reagent Dragendorff in the modification of Mounier, Rf quifenadine = 0.25-0.30 (Sorbfil PTLC-AF-A). The unified HPLC method for identification and quantification of quifenadine has been tested in biogenic extracts from blood according to the developed algorithm of directed analysis. It was found that quifenadine can be identified by retention time – 20.27 ± 0.03 min; retention volume 2026.9 ± 0.34 µl; spectral ratios – 0.634; 0.255; 0.041; 0.022; 0.027; 0.001; 0.001. Equation was used to determine the quifenadine content S = 0.42·10-3 ? + 0.94·10-3 the correlation coefficient was equal to 0.9985.Chromatographic techniques can be recommended for implementation in practice of the Bureau of Forensic Medical Examination, poison control centers, clinical laboratories regarding the study of medicinal substances in biological objects.